Prelude Therapeutics Inc. (PRLD) NASDAQ
$3.87 - (-)
Market Cap: $212.54M
As of 04/24/24 04:00 PM EDT. Market closed.
Prelude Therapeutics Inc. (PRLD)
NASDAQ
$3.87
- (-)
Market Cap: $212.54M
As of 04/24/24 04:00 PM EDT. Market closed.
Add to Portfolio
prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
126
Address
.
PRICE CHART FOR PRELUDE THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$3.94
Previous Close
$3.87
Days Range
$3.87 - $4.13
52 week range
$1.66 - $6.89
Volume
28,584
Avg. Volume (30 days)
42,886
Market Cap
$212.54M
Dividend Yield
-
P/E
-
Shares Outstanding
54,920,594
Open
$3.94
Previous Close
$3.87
Days Range
$3.87 - $4.13
52 week range
$1.66 - $6.89
Volume
28,584
Avg. Volume (30 days)
42,886
Market Cap
$212.54M
Dividend Yield
-
P/E
-
Shares Outstanding
54,920,594
FINANCIAL STATEMENTS FOR PRELUDE THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR PRELUDE THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Huang Jane | President, CMO | Apr 04, 2024 | Option Exercise | $4.74 | 3,347 | 15,865 | 51,287 | Apr 08, 2024, 04:11 PM |
| Huang Jane | President, CMO | Jan 04, 2024 | Option Exercise | $3.77 | 3,844 | 14,492 | 45,259 | Jan 08, 2024, 05:00 PM |
| Huang Jane | President, CMO | Jul 04, 2023 | Option Exercise | $4.65 | 3,242 | 15,075 | 30,353 | Jul 06, 2023, 04:35 PM |
| Vaddi Krishna | CEO | May 25, 2023 | Buy | $5.31 | 900 | 4,779 | 1,067,275 | May 26, 2023, 04:20 PM |
| Vaddi Krishna | CEO | May 24, 2023 | Buy | $5.01 | 1,000 | 5,011 | 1,066,375 | May 26, 2023, 04:20 PM |
| Lim Bryant David | Chief Legal Officer, Corp Sec. | May 24, 2023 | Buy | $5.39 | 2,400 | 12,936 | 2,400 | May 25, 2023, 04:07 PM |
| Chardonnet Laurent | Chief Financial Officer | May 23, 2023 | Buy | $5.50 | 5,000 | 27,500 | 42,165 | May 25, 2023, 04:05 PM |
| Vaddi Krishna | CEO | May 23, 2023 | Buy | $5.63 | 11,856 | 66,749 | 1,065,375 | May 25, 2023, 04:03 PM |
| ORBIMED ADVISORS LLC | Director | May 22, 2023 | Buy | $5.75 | 869,565 | 4,999,999 | 10,119,756 | May 24, 2023, 05:09 PM |
| Bonita David P | Director | May 22, 2023 | Buy | $5.75 | 869,565 | 4,999,999 | 10,119,756 | May 24, 2023, 05:07 PM |
| Huang Jane | President, CMO | Apr 06, 2023 | Sale | $6.12 | 13,280 | 81,274 | 24,220 | Apr 06, 2023, 06:19 PM |
| Vaddi Krishna | CEO | Dec 20, 2022 | Buy | $5.13 | 19,188 | 98,446 | 120,665 | Dec 21, 2022, 04:08 PM |
| Chardonnet Laurent | Chief Financial Officer | Dec 08, 2022 | Buy | $4.76 | 10,000 | 47,600 | 35,873 | Dec 12, 2022, 09:13 AM |
| Chardonnet Laurent | Chief Financial Officer | Jun 01, 2022 | Buy | $4.23 | 10,000 | 42,300 | 24,500 | Jun 01, 2022, 04:31 PM |
| Combs Andrew | EVP, Head of Chemistry | Mar 31, 2022 | Option Exercise | $1.89 | 36,062 | 68,157 | 304,442 | Apr 04, 2022, 05:08 PM |
| Chardonnet Laurent | Chief Financial Officer | Mar 21, 2022 | Option Exercise | $7.51 | 6,500 | 48,815 | 14,500 | Mar 22, 2022, 06:01 PM |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Dec 15, 2021 | Option Exercise | $11.70 | 28,751 | 336,395 | 29,195 | Dec 17, 2021, 05:20 PM |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Dec 15, 2021 | Sale | $13.00 | 28,751 | 373,763 | 444 | Dec 17, 2021, 05:20 PM |
| Combs Andrew | EVP, Head of Chemistry | Dec 14, 2021 | Buy | $11.60 | 4,000 | 46,400 | 268,380 | Dec 15, 2021, 05:21 PM |
| Combs Andrew | EVP, Head of Chemistry | Dec 13, 2021 | Buy | $12.12 | 4,000 | 48,480 | 264,380 | Dec 15, 2021, 05:21 PM |
| Chardonnet Laurent | Chief Financial Officer | Dec 13, 2021 | Option Exercise | $12.28 | 5,000 | 61,400 | 8,000 | Dec 14, 2021, 05:37 PM |
| Vaddi Krishna | President, CEO | Dec 13, 2021 | Option Exercise | $12.13 | 8,000 | 97,035 | 1,053,519 | Dec 14, 2021, 05:36 PM |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Nov 16, 2021 | Option Exercise | $12.85 | 28,751 | 369,450 | 29,195 | Nov 18, 2021, 06:42 PM |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Nov 16, 2021 | Sale | $15.88 | 28,751 | 456,532 | 844 | Nov 18, 2021, 06:42 PM |
| Mauro David J | Chief Medical Officer | Oct 05, 2021 | Option Exercise | $1.89 | 15,000 | 28,350 | 15,000 | Oct 06, 2021, 06:02 PM |
| Mauro David J | Chief Medical Officer | Oct 05, 2021 | Sale | $30.96 | 15,000 | 464,350 | 9,092 | Oct 06, 2021, 06:02 PM |
| Mauro David J | Chief Medical Officer | Sep 07, 2021 | Option Exercise | $1.89 | 15,000 | 28,350 | 15,000 | Sep 09, 2021, 04:53 PM |
| Mauro David J | Chief Medical Officer | Sep 07, 2021 | Sale | $36.69 | 15,000 | 550,283 | 7,513 | Sep 09, 2021, 04:53 PM |
| Pierce Christopher | EVP and Chief of Business Oper | Sep 02, 2021 | Option Exercise | $12.85 | 17,000 | 218,450 | 20,750 | Sep 07, 2021, 07:17 PM |
| Pierce Christopher | EVP and Chief of Business Oper | Sep 02, 2021 | Sale | $41.68 | 17,000 | 708,493 | 17,407 | Sep 07, 2021, 07:17 PM |
| Scherle Peggy | Chief Scientific Officer | Aug 26, 2021 | Option Exercise | $1.43 | 1,700 | 2,431 | 174,620 | Aug 30, 2021, 05:16 PM |
| Scherle Peggy | Chief Scientific Officer | Aug 27, 2021 | Option Exercise | $1.43 | 6,014 | 8,600 | 178,934 | Aug 30, 2021, 05:16 PM |
| Scherle Peggy | Chief Scientific Officer | Aug 27, 2021 | Sale | $35.91 | 6,014 | 215,967 | 176,234 | Aug 30, 2021, 05:16 PM |
| Scherle Peggy | Chief Scientific Officer | Aug 26, 2021 | Sale | $35.19 | 1,700 | 59,819 | 172,920 | Aug 30, 2021, 05:16 PM |
| Piper Brian | Chief Financial Officer | Aug 25, 2021 | Option Exercise | $1.89 | 8,333 | 15,749 | 8,333 | Aug 27, 2021, 08:02 PM |
| Piper Brian | Chief Financial Officer | Aug 25, 2021 | Sale | $33.34 | 8,333 | 277,827 | 6,233 | Aug 27, 2021, 08:02 PM |
| Scherle Peggy | Chief Scientific Officer | Aug 13, 2021 | Option Exercise | $1.54 | 2,286 | 3,526 | 175,206 | Aug 17, 2021, 04:44 PM |
| Scherle Peggy | Chief Scientific Officer | Aug 13, 2021 | Sale | $35.07 | 2,286 | 80,161 | 172,920 | Aug 17, 2021, 04:44 PM |
| Mauro David J | Chief Medical Officer | Aug 05, 2021 | Option Exercise | $1.89 | 15,000 | 28,350 | 15,000 | Aug 09, 2021, 04:26 PM |
| Mauro David J | Chief Medical Officer | Aug 05, 2021 | Sale | $31.09 | 15,000 | 466,394 | 8,884 | Aug 09, 2021, 04:26 PM |
| Scherle Peggy | Chief Scientific Officer | Jul 27, 2021 | Option Exercise | $1.43 | 20,000 | 28,600 | 192,920 | Jul 29, 2021, 07:27 PM |
| Scherle Peggy | Chief Scientific Officer | Jul 27, 2021 | Sale | $35.47 | 20,000 | 709,380 | 173,600 | Jul 29, 2021, 07:27 PM |
| Mauro David J | Chief Medical Officer | Jul 06, 2021 | Option Exercise | $1.89 | 15,000 | 28,350 | 15,000 | Jul 08, 2021, 05:41 PM |
| Mauro David J | Chief Medical Officer | Jul 06, 2021 | Sale | $27.47 | 15,000 | 412,107 | 4,555 | Jul 08, 2021, 05:41 PM |
| Mauro David J | Chief Medical Officer | Jun 07, 2021 | Option Exercise | $1.89 | 15,000 | 28,350 | 15,000 | Jun 09, 2021, 06:24 PM |
| Mauro David J | Chief Medical Officer | Jun 07, 2021 | Sale | $32.44 | 15,000 | 486,622 | 13,600 | Jun 09, 2021, 06:24 PM |
| Piper Brian | Chief Financial Officer | May 25, 2021 | Option Exercise | $1.89 | 8,333 | 15,749 | 8,333 | May 27, 2021, 05:03 PM |
| Piper Brian | Chief Financial Officer | May 25, 2021 | Sale | $34.27 | 8,333 | 285,537 | 5,223 | May 27, 2021, 05:03 PM |
| Scherle Peggy | Chief Scientific Officer | May 07, 2021 | Option Exercise | $1.43 | 10,000 | 14,300 | 182,920 | May 11, 2021, 06:46 PM |
| Scherle Peggy | Chief Scientific Officer | May 07, 2021 | Sale | $40.82 | 10,000 | 408,192 | 178,956 | May 11, 2021, 06:46 PM |
| Pierce Christopher | EVP and Chief of Business Oper | Apr 29, 2021 | Option Exercise | $1.89 | 3,295 | 6,228 | 7,045 | Apr 30, 2021, 06:24 PM |
| Pierce Christopher | EVP and Chief of Business Oper | Apr 29, 2021 | Sale | $40.29 | 3,295 | 132,765 | 3,750 | Apr 30, 2021, 06:24 PM |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Apr 29, 2021 | Option Exercise | $1.89 | 3,223 | 6,091 | 3,667 | Apr 30, 2021, 06:22 PM |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Apr 29, 2021 | Sale | $40.29 | 3,223 | 129,853 | 444 | Apr 30, 2021, 06:22 PM |
| Mauro David J | Chief Medical Officer | Apr 19, 2021 | Option Exercise | $1.89 | 25,000 | 47,250 | 25,000 | Apr 21, 2021, 07:56 PM |
| Mauro David J | Chief Medical Officer | Apr 19, 2021 | Sale | $30.89 | 25,000 | 772,349 | 4,000 | Apr 21, 2021, 07:56 PM |
| Pierce Christopher | EVP and Chief of Business Oper | Apr 08, 2021 | Option Exercise | $1.89 | 200 | 378 | 3,950 | Apr 15, 2021, 07:12 PM |
| Pierce Christopher | EVP and Chief of Business Oper | Apr 08, 2021 | Sale | $40.00 | 200 | 8,000 | 3,750 | Apr 15, 2021, 07:12 PM |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Apr 08, 2021 | Option Exercise | $1.89 | 100 | 189 | 544 | Apr 15, 2021, 07:11 PM |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Apr 08, 2021 | Sale | $40.00 | 100 | 4,000 | 444 | Apr 15, 2021, 07:11 PM |
| Mauro David J | Chief Medical Officer | Apr 08, 2021 | Option Exercise | $1.89 | 9,617 | 18,176 | 9,617 | Apr 15, 2021, 07:09 PM |
| Mauro David J | Chief Medical Officer | Apr 08, 2021 | Sale | $38.35 | 9,617 | 368,852 | 6,343 | Apr 15, 2021, 07:09 PM |
| Scherle Peggy | Chief Scientific Officer | Apr 07, 2021 | Option Exercise | $1.43 | 15,370 | 21,979 | 188,290 | Apr 09, 2021, 05:55 PM |
| Scherle Peggy | Chief Scientific Officer | Apr 07, 2021 | Sale | $39.31 | 15,370 | 604,144 | 180,001 | Apr 09, 2021, 05:55 PM |
| Pierce Christopher | EVP and Chief of Business Oper | Apr 07, 2021 | Option Exercise | $1.89 | 828 | 1,565 | 4,578 | Apr 09, 2021, 05:53 PM |
| Pierce Christopher | EVP and Chief of Business Oper | Apr 07, 2021 | Sale | $40.08 | 828 | 33,188 | 3,750 | Apr 09, 2021, 05:53 PM |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Apr 07, 2021 | Option Exercise | $1.89 | 1,000 | 1,890 | 1,444 | Apr 09, 2021, 05:52 PM |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Apr 07, 2021 | Sale | $40.04 | 1,000 | 40,043 | 444 | Apr 09, 2021, 05:52 PM |
| Mauro David J | Chief Medical Officer | Apr 07, 2021 | Option Exercise | $1.89 | 15,383 | 29,074 | 15,383 | Apr 09, 2021, 05:50 PM |
| Mauro David J | Chief Medical Officer | Apr 07, 2021 | Sale | $39.33 | 15,383 | 605,023 | 7,083 | Apr 09, 2021, 05:50 PM |
| BAKER BROS. ADVISORS LP | Director | Jan 27, 2021 | Option Exercise | $12.85 | 10,376 | 133,332 | 9,252,951 | Jan 29, 2021, 07:04 PM |
| Bonita David P | Director | Sep 25, 2020 | Buy | $19.00 | 1,236,800 | 23,499,200 | 917,412 | Sep 30, 2020, 07:52 PM |
| BAKER BROS. ADVISORS LP | Director | Sep 29, 2020 | Buy | $19.00 | 1,578,947 | 29,999,993 | 9,247,763 | Sep 30, 2020, 06:37 PM |
| Combs Andrew | EVP, Head of Chemistry | Sep 29, 2020 | Buy | $19.00 | 1,000 | 19,000 | 260,380 | Sep 29, 2020, 08:11 PM |
| ORBIMED ADVISORS LLC | Director | Sep 25, 2020 | Buy | $19.00 | 1,236,800 | 23,499,200 | 917,412 | Sep 29, 2020, 08:10 PM |
| Dier Mardi | Director | Sep 29, 2020 | Buy | $19.00 | 10,000 | 190,000 | 10,000 | Sep 29, 2020, 08:09 PM |
| Morosini Deborah | EVP, Chief of Clinical Affairs | Sep 29, 2020 | Buy | $19.00 | 444 | 8,436 | 444 | Sep 29, 2020, 08:08 PM |
| Pierce Christopher | EVP and Chief of Business Oper | Sep 29, 2020 | Buy | $19.00 | 3,750 | 71,250 | 3,750 | Sep 29, 2020, 08:07 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Huang Jane | President, CMO | 04/04/2024 | 15,865 |
| Huang Jane | President, CMO | 01/04/2024 | 14,492 |
| Huang Jane | President, CMO | 07/04/2023 | 15,075 |
| Vaddi Krishna | CEO | 05/25/2023 | 4,779 |
| Vaddi Krishna | CEO | 05/24/2023 | 5,011 |
| Lim Bryant David | Chief Legal Officer, Corp Sec. | 05/24/2023 | 12,936 |
| Chardonnet Laurent | Chief Financial Officer | 05/23/2023 | 27,500 |
| Vaddi Krishna | CEO | 05/23/2023 | 66,749 |
| ORBIMED ADVISORS LLC | Director | 05/22/2023 | 4,999,999 |
| Bonita David P | Director | 05/22/2023 | 4,999,999 |
| Huang Jane | President, CMO | 04/06/2023 | 81,274 |
| Vaddi Krishna | CEO | 12/20/2022 | 98,446 |
| Chardonnet Laurent | Chief Financial Officer | 12/08/2022 | 47,600 |
| Chardonnet Laurent | Chief Financial Officer | 06/01/2022 | 42,300 |
| Combs Andrew | EVP, Head of Chemistry | 03/31/2022 | 68,157 |
| Chardonnet Laurent | Chief Financial Officer | 03/21/2022 | 48,815 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 12/15/2021 | 336,395 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 12/15/2021 | 373,763 |
| Combs Andrew | EVP, Head of Chemistry | 12/14/2021 | 46,400 |
| Combs Andrew | EVP, Head of Chemistry | 12/13/2021 | 48,480 |
| Chardonnet Laurent | Chief Financial Officer | 12/13/2021 | 61,400 |
| Vaddi Krishna | President, CEO | 12/13/2021 | 97,035 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 11/16/2021 | 369,450 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 11/16/2021 | 456,532 |
| Mauro David J | Chief Medical Officer | 10/05/2021 | 28,350 |
| Mauro David J | Chief Medical Officer | 10/05/2021 | 464,350 |
| Mauro David J | Chief Medical Officer | 09/07/2021 | 28,350 |
| Mauro David J | Chief Medical Officer | 09/07/2021 | 550,283 |
| Pierce Christopher | EVP and Chief of Business Oper | 09/02/2021 | 218,450 |
| Pierce Christopher | EVP and Chief of Business Oper | 09/02/2021 | 708,493 |
| Scherle Peggy | Chief Scientific Officer | 08/26/2021 | 2,431 |
| Scherle Peggy | Chief Scientific Officer | 08/27/2021 | 8,600 |
| Scherle Peggy | Chief Scientific Officer | 08/27/2021 | 215,967 |
| Scherle Peggy | Chief Scientific Officer | 08/26/2021 | 59,819 |
| Piper Brian | Chief Financial Officer | 08/25/2021 | 15,749 |
| Piper Brian | Chief Financial Officer | 08/25/2021 | 277,827 |
| Scherle Peggy | Chief Scientific Officer | 08/13/2021 | 3,526 |
| Scherle Peggy | Chief Scientific Officer | 08/13/2021 | 80,161 |
| Mauro David J | Chief Medical Officer | 08/05/2021 | 28,350 |
| Mauro David J | Chief Medical Officer | 08/05/2021 | 466,394 |
| Scherle Peggy | Chief Scientific Officer | 07/27/2021 | 28,600 |
| Scherle Peggy | Chief Scientific Officer | 07/27/2021 | 709,380 |
| Mauro David J | Chief Medical Officer | 07/06/2021 | 28,350 |
| Mauro David J | Chief Medical Officer | 07/06/2021 | 412,107 |
| Mauro David J | Chief Medical Officer | 06/07/2021 | 28,350 |
| Mauro David J | Chief Medical Officer | 06/07/2021 | 486,622 |
| Piper Brian | Chief Financial Officer | 05/25/2021 | 15,749 |
| Piper Brian | Chief Financial Officer | 05/25/2021 | 285,537 |
| Scherle Peggy | Chief Scientific Officer | 05/07/2021 | 14,300 |
| Scherle Peggy | Chief Scientific Officer | 05/07/2021 | 408,192 |
| Pierce Christopher | EVP and Chief of Business Oper | 04/29/2021 | 6,228 |
| Pierce Christopher | EVP and Chief of Business Oper | 04/29/2021 | 132,765 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 04/29/2021 | 6,091 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 04/29/2021 | 129,853 |
| Mauro David J | Chief Medical Officer | 04/19/2021 | 47,250 |
| Mauro David J | Chief Medical Officer | 04/19/2021 | 772,349 |
| Pierce Christopher | EVP and Chief of Business Oper | 04/08/2021 | 378 |
| Pierce Christopher | EVP and Chief of Business Oper | 04/08/2021 | 8,000 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 04/08/2021 | 189 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 04/08/2021 | 4,000 |
| Mauro David J | Chief Medical Officer | 04/08/2021 | 18,176 |
| Mauro David J | Chief Medical Officer | 04/08/2021 | 368,852 |
| Scherle Peggy | Chief Scientific Officer | 04/07/2021 | 21,979 |
| Scherle Peggy | Chief Scientific Officer | 04/07/2021 | 604,144 |
| Pierce Christopher | EVP and Chief of Business Oper | 04/07/2021 | 1,565 |
| Pierce Christopher | EVP and Chief of Business Oper | 04/07/2021 | 33,188 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 04/07/2021 | 1,890 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 04/07/2021 | 40,043 |
| Mauro David J | Chief Medical Officer | 04/07/2021 | 29,074 |
| Mauro David J | Chief Medical Officer | 04/07/2021 | 605,023 |
| BAKER BROS. ADVISORS LP | Director | 01/27/2021 | 133,332 |
| Bonita David P | Director | 09/25/2020 | 23,499,200 |
| BAKER BROS. ADVISORS LP | Director | 09/29/2020 | 29,999,993 |
| Combs Andrew | EVP, Head of Chemistry | 09/29/2020 | 19,000 |
| ORBIMED ADVISORS LLC | Director | 09/25/2020 | 23,499,200 |
| Dier Mardi | Director | 09/29/2020 | 190,000 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 09/29/2020 | 8,436 |
| Pierce Christopher | EVP and Chief of Business Oper | 09/29/2020 | 71,250 |
Load More Insider Transactions
FUNDS WITH A POSITION IN PRELUDE THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10,909,256 | 0.93% | No change | Other |
| BAKER BROS. ADVISORS LP | 10,123,824 | 0.49% | No change | Other |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,133,000 | 0.33% | New | Other |
| BLACKROCK INC. | 1,095,589 | 0.00012% | 2.54% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 349,367 | 0.00016% | 5.52% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 216,400 | 0.00143% | 55.27% | Other |
CHANGE IN SHARES OUTSTANDING FOR PRELUDE THERAPEUTICS INC
STOCK BUYBACKS FOR PRELUDE THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
2.89%
1Q
06/30/2023
23.74%
2Q
12/31/2022
45.93%
4Q
09/30/2022
46.66%
5Q
06/30/2022
47.20%
6Q
03/31/2022
47.86%
7Q
12/31/2021
49.10%
8Q
09/30/2021
50.21%
9Q
06/30/2021
51.10%
10Q
03/31/2021
54.23%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR PRELUDE THERAPEUTICS INC
LOADING...